Tissue-specific promoters for cancer gene therapy (Q35779378)

10 August 2017

1 reference

title

Tissue-specific promoters for cancer gene therapy (English)

1 reference

10 August 2017

0 references

1 reference

2

Akseli Hemminki

1 reference

10 August 2017

Kirsi Saukkonen

1

1 reference

PubMed ID

15155160

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

5

1 reference

10 August 2017

683-696

1 reference

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

From molecular changes to customised therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Latest development in viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

NeoR-based transduced T lymphocytes detected by real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Adenoviruses in oncology: a viable option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

The promise and potential hazards of adenovirus gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Gene therapy of cancer with interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Replicative adenoviruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Replication-selective adenoviruses as oncolytic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

New developments in the virus therapy of cancer: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Gene therapy: designer promoters for tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Cyclooxygenase‐2 and gastric carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Telomerase, Cell Immortality, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Specific association of human telomerase activity with immortal cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Telomerase-dependent oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Tissue-specific promoters in gene therapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Emerging roles for E2F: Beyond the G1/S transition and DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Tissue-specific gene therapy directed to tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

In vivo imaging and tumor therapy with the sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Functional delivery of large genomic DNA to human cells with a peptide-lipid vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.5.683

21 January 2018

Identifiers

DOI

10.1517/14712598.4.5.683

1 reference

10 August 2017

1 reference

PubMed ID

15155160